Lv1
50 积分 2025-12-22 加入
Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
2个月前
已完结
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials
2个月前
已完结
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
2个月前
已完结
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
2个月前
已完结
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
2个月前
已完结
British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025
2个月前
已完结
克罗恩病治疗新目标：透壁愈合
2个月前
已完结
Successful treatment of Crohn’s disease-related peripheral spondyloarthritis with upadacitinib: two case reports and case-based review
2个月前
已关闭
Triple biologic therapy for refractory Crohn’s disease
2个月前
已完结
Upadacitinib in a patient with concurrent refractory axial Spondyloarthritis and inflammatory bowel disease: A case report
2个月前
已关闭
皖公网安备34019202002308
